and we have all the facts that you need to know, so let s get smarter. we start with new details about covid omicron variant. the situation changing by the minute. with new cases popping up in countries around the world including japan and the french territory of the reunion of the indian ocean. and just this morning, regeneron saying that its antibody drug cocktail loses effectiveness against this variant. all this as president biden urges caution here at home. this variant is a cause for concern, not a cause for panic. the best protection, i know you are tired of hearing me say this, the best protection against this new variant or any of the variants out there, the ones that we ve been dealing with already, is getting fully vaccinated. getting a booster shot. are lockdowns off the table? yes, for now. why is that? because if people are vax
Roche s COVID-19 antibody cocktail launched in India at Rs 59,750 per dose
Antibody cocktail is to be administered for treatment of mild to moderate coronavirus disease in adults and pediatric patients who are confirmed to be infected with SARS-COV2 and are at high risk of developing severe COVID-19 disease and do not require oxygen
BusinessToday.In | May 24, 2021 | Updated 11:41 IST
Cocktail has been shown to help high-risk Covid patients before their condition worsens
Roche India and Cipla Limited, in a joint statement today, said the first batch of the antibody cocktail Casirivimab and Imdevimab is now available in India, while a second batch will be made available by mid-June. The price for each patient dose, a combined dose of 1,200 mg (600 mg of Casirivimab and 600 mg of Imdevimab), will be Rs 59,750, inclusive of all taxes. The MRP for the multi dose pack, each pack can treat two patients, is Rs 119,500.
India approves Roche s antibody cocktail to treat COVID-19; Cipla to distribute the drug
The approval was granted by the Central Drugs Standards Control Organisation (CDSO) basis data filed with the US regulators as well as the scientific opinion of a European regulatory panel
BusinessToday.In | May 6, 2021 | Updated 09:53 IST
A logo of Swiss pharmaceutical company Roche in Rotkreuz, Switzerland, April 12, 2012. (Photo: Reuters)
Pharma giant Roche India has received the Emergency Use Authorisation (EUA) for a COVID-19 antibody-drug cocktail Casirivimab and Imdevimab in the country for the treatment of coronavirus patients. The drug cocktail is developed by Roche and Regeneron.
The approval was granted by the Central Drugs Standards Control Organisation (CDSCO) basis data filed with the US regulators as well as the scientific opinion of a European regulatory panel. This will further expand India s arsenal of drugs to fight a massive second wave of COVID-19.